This Super Software Stock Has Almost Doubled Since I Bought It in April. Here's Why It Has Room to Run.

Atlassian reported $1.8 billion in fiscal Q3 revenue, up 32% year over year and above the $1.7 billion consensus, easing concerns that AI is hurting software demand. ARR from Rovo customers grew at twice the pace of non-Rovo customers, while the new Flex pricing model could support further growth. The stock has rebounded 83% from its April low and still trades at a 4.5x price-to-sales ratio, below its three-year average of 10.7x.

Analysis

TEAM is turning the market’s core objection into a distribution advantage: AI is not just a feature layer, it is a usage-expansion catalyst that makes the platform stickier and broadens monetization beyond classic per-seat pricing. The bigger implication is that the company is shifting from a “replacement risk” narrative to a workflow-orchestration narrative, where AI increases the value of the control plane rather than commoditizing it. That tends to favor vendors with deep admin/security hooks and embedded data exhaust, because the moat moves from UI to governance and identity.

The Flex pricing rollout matters more than the headline growth rate. Moving from seat economics to budget-based consumption can front-load adoption, reduce procurement friction, and raise net retention by letting customers experiment before standardizing spend. The second-order effect is likely a mix shift toward larger enterprise accounts and more variable revenue timing, which can create brief skepticism around quality of growth but usually supports a higher terminal multiple if expansion holds.

The key risk is not AI displacement over the next quarter; it is margin dilution and execution risk over the next 6-12 months if AI features increase compute/support costs faster than monetization. Another risk is that a strong top-line print invites a crowded re-rating, leaving the stock vulnerable if subsequent quarters show slower Rovo attach or Flex cannibalizes near-term ARPU. Consensus may be underestimating how much of the upside is already in “AI skepticism fading,” but still underpricing the possibility that Atlassian becomes a broader enterprise workflow layer rather than just a dev-tools vendor.

Key Decisions for Investors

• Go long TEAM on pullbacks over the next 2-4 weeks; target a re-rate toward prior average sales multiple if Rovo/Flex adoption sustains, with downside protected by recent fundamental inflection.
• Buy TEAM Jan-2027 call spreads to express medium-term upside while limiting valuation-compression risk; best payoff if the market grants a higher terminal multiple over 12-18 months.
• Pair long TEAM / short a basket of seat-based legacy collaboration or point software names over 3-6 months; the thesis is that flexible consumption and AI-enabled workflow integration accelerate share gains versus static licensing models.
• Avoid chasing the move after the recent rerating; initiate only on weakness or after the next earnings set-up, because the stock is now more sensitive to any slowdown in ARR conversion.
• For hedged accounts, consider a small long TEAM vs short CRWD pair only if you want to isolate pricing-model expansion risk; otherwise CRWD remains the cleaner AI-commercialization beneficiary.